

## MT2024-16: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Hidradenitis Suppurativa

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

Diagnosis of Hidradenitis Suppurativa

---

**Exclusion Criteria:**

History of Crohn's disease

### Conditions & Interventions

**Conditions:**

Dermatology (Skin, Hair & Nails)

**Keywords:**

Clinics and Surgery Center (CSC), Hidradenitis suppurativa

### More Information

**Description:** This research study is for people who have Hidradenitis Suppurativa (HS) and it is moderate or severe in intensity and have been treated with at least one conventional therapy for HS. This study involves the investigational drug SBT777101, which is created by genetically modifying a patient's own immune cells. The word "investigational" means that this drug has not been approved by the U.S. Food and Drug Administration (FDA) for marketing. SBT777101 is being developed to treat people with hidradenitis suppurativa (HS).

**Study Contact:** Gretchen Bellefeuille - belle116@umn.edu

**Principal Investigator:** Noah Goldfarb

**IRB**

**Number:** STUDY00021432

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.